• OPEN AN ACCOUNT
Indian Indices
Nifty
24,334.20 -1.75
(-0.01%)
Sensex
80,242.24 -46.14
( -0.06%)
Bank Nifty
55,087.15 -304.10
( -0.55%)
Nifty IT
35,794.95 -125.45
( -0.35%)
Global Indices
Nasdaq
40,683.88 135.26
(0.33%)
Dow Jones
5,589.17 7.34
(0.13%)
Hang Seng
36,431.41 386.03
(1.07%)
Nikkei 225
8,496.80 1.95
(0.02%)
Forex
USD-INR
85.16 -0.04
(-0.05%)
EUR-INR
97.01 0.08
(0.09%)
GBP-INR
114.18 0.35
(0.31%)
JPY-INR
0.60 0.00
(0.42%)

EQUITY - MARKET SCREENER

IRB Infrastructure Trust
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
78873
INE0C8K23012
125.0503133
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
IRBIT
20.11
25811.84
EPS(TTM)
Face Value()
Div & Yield %
10.95
100
2.36
 

sharanam infraproject & trading ltd
Sun Pharma receives favourable ruling in preliminary injunction delaying launch of LEQSELVI™
Apr 10,2025
Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI™ (deuruxolitinib) in the United States.

Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately.

While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect.

The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI™. The Company will disclose LEQSELVI™ launch plans in due course of time.